The Impact of Osteoblastic Differentiation on Osteosarcomagenesis in the Mouse

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2014 Oct 28

PMID 25347737

Citations 32

Authors

T Quist

H Jin

J-F Zhu

K Smith-Fry

M R Capecchi

K B Jones

Affiliations

Soon will be listed here.

Abstract

Osteosarcomas remain an enigmatic group of malignancies that share in common the presence of transformed cells producing osteoid matrix, even if these cells comprise a minority of the tumor volume. The differentiation state of osteosarcomas has therefore become a topic of interest and challenge to those who study this disease. In order to test how the cell of origin contributes to the final state of differentiation in the transformed cells, we compared the relative tumorigenicity of Cre-LoxP conditional disruption of the cell cycle checkpoint tumor-suppressor genes Trp53 and Rb1 using Prx1-Cre, Collagen-1α1-Cre and Osteocalcin-Cre to transform undifferentiated mesenchyme, preosteoblasts and mature osteoblasts, respectively. The Prx1 and Col1α1 lineages developed tumors with nearly complete penetrance, as anticipated. Osteosarcomas also developed in 44% of Oc-Cre;Rb1(fl/fl);Trp53(fl/fl) mice. We confirmed using 5-ethynyl-2'-deoxyuridine click chemistry that the Oc-Cre lineage includes very few actively cycling cells. By assessing radiographic mineralization and histological osteoid production, the differentiation state of tumors did not correlate with the differentiation state of the lineage of origin. Some of the osteocalcin-lineage-derived osteosarcomas were among the least osteoblastic. Osteocalcin immunohistochemistry in tumors correlated well with the expression of DNA methyl transferases, suggesting that silencing of these epigenetic regulators may influence the final differentiation state of an osteosarcoma. Transformation of differentiated, minimally proliferative osteoblasts is possible but may require such an epigenetic reprogramming that the tumors no longer resemble their differentiated origins.

Citing Articles

PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours.

Takihira S, Yamada D, Osone T, Takao T, Sakaguchi M, Hakozaki M Br J Cancer. 2024; 130(9):1493-1504.

PMID: 38448751 PMC: 11058259. DOI: 10.1038/s41416-024-02632-8.

Multi-Anticancer Activities of Phytoestrogens in Human Osteosarcoma.

Cimmino A, Fasciglione G, Gioia M, Marini S, Ciaccio C Int J Mol Sci. 2023; 24(17).

PMID: 37686148 PMC: 10487502. DOI: 10.3390/ijms241713344.

Cellular and Genetic Background of Osteosarcoma.

Urlic I, Jovicic M, Ostojic K, Ivkovic A Curr Issues Mol Biol. 2023; 45(5):4344-4358.

PMID: 37232745 PMC: 10217763. DOI: 10.3390/cimb45050276.

Cellular dynamics of distinct skeletal cells and the development of osteosarcoma.

Otani S, Ohnuma M, Ito K, Matsushita Y Front Endocrinol (Lausanne). 2023; 14:1181204.

PMID: 37229448 PMC: 10203529. DOI: 10.3389/fendo.2023.1181204.

Mesenchymal loss of p53 alters stem cell capacity and models human soft tissue sarcoma traits.

Sorimachi Y, Kobayashi H, Shiozawa Y, Koide S, Nakato R, Shimizu Y Stem Cell Reports. 2023; 18(5):1211-1226.

PMID: 37059101 PMC: 10202654. DOI: 10.1016/j.stemcr.2023.03.009.

References

Thomas D, Carty S, Piscopo D, Lee J, Wang W, Forrester W . The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell. 2001; 8(2):303-16. DOI: 10.1016/s1097-2765(01)00327-6. View

Weiss A, Khoury J, Hoffer F, Wu J, Billups C, Heck R . Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Cancer. 2007; 109(8):1627-37. DOI: 10.1002/cncr.22574. View

Ragland B, Bell W, Lopez R, Siegal G . Cytogenetics and molecular biology of osteosarcoma. Lab Invest. 2002; 82(4):365-73. DOI: 10.1038/labinvest.3780431. View

Haydon R, Zhou L, Feng T, Breyer B, Cheng H, Jiang W . Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res. 2002; 8(5):1288-94. PMC: 4527755. View

Dacquin R, Starbuck M, Schinke T, Karsenty G . Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn. 2002; 224(2):245-51. DOI: 10.1002/dvdy.10100. View

Dick J . Breast cancer stem cells revealed. Proc Natl Acad Sci U S A. 2003; 100(7):3547-9. PMC: 152954. DOI: 10.1073/pnas.0830967100. View

Liu F, Woitge H, Braut A, Kronenberg M, Lichtler A, Mina M . Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol. 2004; 48(7):645-53. DOI: 10.1387/ijdb.041816fl. View

Sharkey F . Morphometric analysis of differentiation in human breast carcinoma. Tumor heterogeneity. Arch Pathol Lab Med. 1983; 107(8):411-4. View

Liu F, Malaval L, Gupta A, Aubin J . Simultaneous detection of multiple bone-related mRNAs and protein expression during osteoblast differentiation: polymerase chain reaction and immunocytochemical studies at the single cell level. Dev Biol. 1994; 166(1):220-34. DOI: 10.1006/dbio.1994.1309. View

10.

Damron T, Ward W, Stewart A . Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. 2007; 459:40-7. DOI: 10.1097/BLO.0b013e318059b8c9. View

11.

Walkley C, Shea J, Sims N, Purton L, Orkin S . Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 2007; 129(6):1081-95. PMC: 2768301. DOI: 10.1016/j.cell.2007.03.055. View

12.

Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R . Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007; 67(17):8216-22. DOI: 10.1158/0008-5472.CAN-07-0999. View

13.

Desandes E . Survival from adolescent cancer. Cancer Treat Rev. 2007; 33(7):609-15. DOI: 10.1016/j.ctrv.2006.12.007. View

14.

Yeo H, Beck L, Thompson S, Farach-Carson M, McDonald J, Clemens T . Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. J Biol Chem. 2007; 282(48):35318-27. DOI: 10.1074/jbc.M702435200. View

15.

Walkley C, Qudsi R, Sankaran V, Perry J, Gostissa M, Roth S . Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22(12):1662-76. PMC: 2428063. DOI: 10.1101/gad.1656808. View

16.

Berman S, Calo E, Landman A, Danielian P, Miller E, West J . Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A. 2008; 105(33):11851-6. PMC: 2575280. DOI: 10.1073/pnas.0805462105. View

17.

Lin P, Pandey M, Jin F, Xiong S, Deavers M, Parant J . EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res. 2008; 68(21):8968-75. PMC: 4167779. DOI: 10.1158/0008-5472.CAN-08-0573. View

18.

Gutierrez G, Kong E, Sabbagh Y, Brown N, Lee J, Demay M . Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. Proc Natl Acad Sci U S A. 2008; 105(47):18402-7. PMC: 2585042. DOI: 10.1073/pnas.0805925105. View

19.

Levings P, McGarry S, Currie T, Nickerson D, McClellan S, Ghivizzani S . Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 2009; 69(14):5648-55. PMC: 2841219. DOI: 10.1158/0008-5472.CAN-08-3580. View

20.

San Martin I, Varela N, Gaete M, Villegas K, Osorio M, Tapia J . Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells. J Cell Physiol. 2009; 221(3):560-71. PMC: 3066433. DOI: 10.1002/jcp.21894. View